Oncology Clinical Trials 2023

What are the top hospitals conducting oncology research?

When it comes to groundbreaking clinical trials in the field of oncology, several hospitals have made significant contributions. In New York City, Memorial Sloan Kettering Cancer Center takes the lead with an impressive 10 ongoing trials and a remarkable history of 260 completed studies since their first recorded trial in 1977. This prestigious institution has been at the forefront of cancer research for decades, constantly striving to find innovative treatments and improve patient outcomes.

Down in Houston, Texas, The University of Texas MD Anderson Cancer Center is making waves as well. With nine active oncology trials and a portfolio that boasts 88 completed studies since their inaugural trial in 2006, this renowned center is dedicated to pushing the boundaries of cancer research and providing cutting-edge care to patients from around the world.

In Dallas, GSK Investigational Site has emerged as an important player in the field with eight active oncology trials currently underway. Since recording their first trial in 2008, they have conducted a total of 16 studies thus far. The dedication shown by this site highlights its commitment to advancing our understanding and treatment options for various types of cancers.

Heading back up north to Boston's Massachusettsf oncology, several hospitals have made significant contributions. In New York City, Memorial Sloan Kettering Cancer Center takes the lead with an impressive 10 ongoing trials and a remarkable history of 260 completed studies since their first recorded trial in 1977. This prestigious institution has been at the forefront of cancer research for decades, constantly striving to find innovative treatments and improve patient outcomes.

Down in Houston, Texas, The University of Texas MD Anderson Cancer Center is making waves as well. With nine active oncology trials and a portfolio that boasts 88 completed studies since their inaugural trial in 2006, this renowned center is dedicated to pushing the boundaries of cancer research and providing cutting-edge care to patients from around the world.

In Dallas, GSK Investigational Site has emerged as an important player in the field with eight active oncology trials currently underway. Since recording their first trial in 2008, they have conducted a total of 16 studies thus far. The dedication shown by this site highlights its commitment to advancing our understanding and treatment options for various types of cancers.

Heading back up north to Boston's Massachusetts General Hospital (MGH), medical professionals are engaged in eight active oncology trials while having achieved an impressive tally of176 previous investigations since conducting its initial trial backin1999.MGH's contribution towards pioneering new treatments underscores its commitment towards better outcomes for patients battling cancer.

Lastly,GSK Investigational Site based outof Toronto also deserves recognition for its efforts withinthe realmofoncologicalclinicaltrials.Thiscenteriscurrentlyengagedineightactiveandongoingtreatmentsforvariousformsoccancers.Sincemakingitsmarkin2014,thisinvestigationalrehasconducted25studiesfocusedonimprovingpatientcareandtacklingtheproblemsofwinningthesefightsagainstthedisease.

These esteemed institutions stand as beacons of hope and progress in the fight against cancer. Through their tireless efforts, researchers and clinicians are constantly striving to find new ways to prevent, diagnose, and treat this devastating disease. Each trial conducted brings us closer to more effective therapies and improved outcomes for patients worldwide.

Which are the best cities for oncology clinical trials?

When it comes to oncology clinical trials, several cities have emerged as hotspots for cutting-edge research. New York City leads the way with 50 active trials investigating a diverse range of treatments such as Arm 3: JAKi Naïve Combination Arm, Gene-modified (GM) T cell therapy, and BLU-451. Houston, Texas closely follows with 49 ongoing studies focused on interventions like SAR443216-Dose Expansion for metastatic gastric cancers with HER2 low expression and CC-90011. Additionally, Boston, Massachusettso oncology clinical trials, several cities have emerged as hotspots for cutting-edge research. New York City leads the way with 50 active trials investigating a diverse range of treatments such as Arm 3: JAKi Naïve Combination Arm, Gene-modified (GM) T cell therapy, and BLU-451. Houston, Texas closely follows with 49 ongoing studies focused on interventions like SAR443216-Dose Expansion for metastatic gastric cancers with HER2 low expression and CC-90011. Additionally, Boston, Massachusetts offers 33 active trials exploring therapies such as P-PSMA-101 CAR-T cells and GM T cell therapy. These cities showcase a dedication to advancing oncology care through rigorous clinical trials that pave the way for improved treatment options for cancer patients.

Which are the top treatments for oncology being explored in clinical trials?

Exciting advances in oncology research are taking place through various clinical trials, focusing on the exploration of top treatments. Gemcitabine stands out with 81 all-time oncology trials and continues to be investigated in two active studies since its introduction in 2001. Joining the ranks is EMB-01, a newer contender introduced in 2018, currently being tested in two active oncology trials alongside BI 907828, both showing promise for future treatment options. Another intriguing development is ATLCAR.CD30 cells—an innovative therapy first listed in 2016—with ongoing investigation occurring through two active oncology trials. These cutting-edge approaches offer hope for improving outcomes and transforming cancer1 all-time oncology trials and continues to be investigated in two active studies since its introduction in 2001. Joining the ranks is EMB-01, a newer contender introduced in 2018, currently being tested in two active oncology trials alongside BI 907828, both showing promise for future treatment options. Another intriguing development is ATLCAR.CD30 cells—an innovative therapy first listed in 2016—with ongoing investigation occurring through two active oncology trials. These cutting-edge approaches offer hope for improving outcomes and transforming cancer care.

What are the most recent clinical trials for oncology?

Exciting advancements are taking place in the field of oncology, with recent clinical trials offering new possibilities for patients. One notable trial is exploring a Part B Expansion, which aims to expand on previous findings and assess safety and efficacy in a larger cohort. Additionally, Arm 1 is investigating an innovative approach to treatment in Phase 2, providing hope for improved outcomes. Another study focuses on the potential benefits of combining triplet therapies for certain types of cancer, aiming to enhance overall response rates. Furthermore, MDK-703 shows promise when utilized alongside checkpoint inhibitors in both Phase 1 and Phase 2 trials. Lastly but not leastly VIP236's dose escalation trial seeks to determine optimal dosage levels for effective treatment options down the line.. These ongoing trials offer immense potential and bring us closer towards more effective strategies against cancer.

What oncology clinical trials were recently completed?

Numerous oncology clinical trials have recently concluded, showcasing the progress being made in cancer research. In April 2022, OncoNano Medicine's pegsitacianine trial and Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA trial achieved their completion milestones. Earlier this year, Adagene Inc.'s ADG116 trial was finalized in February 2022. Other significant completed trials include HiberCell's Pembrolizumab study (November 2021), AstraZeneca's Capivasertib study (October 2021), and Mirati Therapeutics' MRTX849 study (August 2021). These examples highlight the commitment of researchers to advancing treatments for various types of cancers and offer hope to patients worldwide.